[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Hybio Pharmaceutical Co Ltd (300199) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

October 2018 | 24 pages | ID: H9871DBF237EN
GlobalData

US$ 250.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Summary

Hybio Pharmaceutical Co Ltd (Hybio) is a peptide pharmaceutical company that develops and manufactures of polypeptide drugs. The company offers peptide finished dosage products and peptide active pharmaceutical ingredients. Its finished dosage products include desmopressin for injection, terlipressin for injection, sodium ozagrel for injection, oxytocin for injection, and omeprazole sodium for injection, among others. Hybio provides active pharmaceutical ingredients such as abarelix, calcitonin, copaxone, antide, desmopression, alarelin, bivalirudin, desirudin, elecatonin, fertirelin, ganadorelin, histrelin, leuprorelin, vapreotide and haxapeptide. The company conducts synthesis, purification, lyophilization, quality research, formulation study and pilot production of polypeptide drugs. It markets its products in the US, Canada, Italy, India, Germany and Russia. Hybio is headquartered in Shenzhen, China.

Hybio Pharmaceutical Co Ltd (300199) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope
  • Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
  • Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
  • Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
  • Key Competitors - A list of the key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.
Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
  • The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion/divestiture strategy
  • The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
  • Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
  • Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
  • Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company.
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018
Hybio Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details
Private Equity
AMW to Sell Shares to Hybio Pharma and YF Capital Led Consortium
Licensing Agreements
Shenzhen Hybio Pharma Enters into Licensing Agreement with Akorn
Hybio Pharma Enters into Licensing Agreement
Equity Offering
Hybio Pharma Raises USD98 Million in Private Placement of Shares
Hybio Pharma to Raise USD71.5 Million in Private Placement of Shares
Debt Offering
Hybio Pharma to Raise USD157.8 Million in Public Offering of Medium Terms Notes
Hybio Pharma Plans to Raise up to USD145.5 Million in Public Offering of Bonds Due 2022
Hybio Pharma Plans to Raise up to USD147.5 Million in Public Offering of Notes
Acquisition
Hybio Pharma to Acquire Pharma Company for USD214.6 Million
Hybio Pharmaceutical Co Ltd - Key Competitors
Hybio Pharmaceutical Co Ltd - Key Employees
Hybio Pharmaceutical Co Ltd - Locations And Subsidiaries
Head Office
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018
Hybio Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018
Hybio Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018
AMW to Sell Shares to Hybio Pharma and YF Capital Led Consortium
Shenzhen Hybio Pharma Enters into Licensing Agreement with Akorn
Hybio Pharma Enters into Licensing Agreement
Hybio Pharma Raises USD98 Million in Private Placement of Shares
Hybio Pharma to Raise USD71.5 Million in Private Placement of Shares
Hybio Pharma to Raise USD157.8 Million in Public Offering of Medium Terms Notes
Hybio Pharma Plans to Raise up to USD145.5 Million in Public Offering of Bonds Due 2022
Hybio Pharma Plans to Raise up to USD147.5 Million in Public Offering of Notes
Hybio Pharma to Acquire Pharma Company for USD214.6 Million
Hybio Pharmaceutical Co Ltd, Key Competitors
Hybio Pharmaceutical Co Ltd, Key Employees

LIST OF FIGURES

Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018
Hybio Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018


More Publications